Literature DB >> 16113629

Depression and Huntington's disease: prevalence, clinical manifestations, etiology, and treatment.

J R Slaughter1, M P Martens, K A Slaughter.   

Abstract

In order to determine the extent to which depression complicates Huntington's disease (HD), we have analyzed the existing literature on depression in HD in order to report the prevalence, clinical manifestations, and treatment of HD depression. By means of MEDLINE literature searches and reviews of HD articles' bibliographies, we identified for our analysis 16 HD depression studies. Our results indicate that the prevalence of depression is 30% for all HD patients. Clinical manifestations of HD depression include a marked increased risk for suicide. The etiology of HD depression is unclear, but may be due to a number of factors, such as dysfunction in the caudate nucleus, dysfunction in the ventral striatum, and various genetic factors that are discussed in this review. Case reports and case series support the efficacy of standard antidepressant interventions in resolving symptoms of depression. Efficacious treatments reported in the literature include tricyclic antidepressants, monoamine oxidase inhibitors, selective serotonin reuptake inhibitors, and electroconvulsive therapy. In this study, the successful anecdotal treatment of seven consecutive HD depressed patients with sertraline suggests that sertraline may be a safe and efficacious treatment of HD depression.

Entities:  

Year:  2001        PMID: 16113629     DOI: 10.1017/s109285290002201x

Source DB:  PubMed          Journal:  CNS Spectr        ISSN: 1092-8529            Impact factor:   3.790


  15 in total

1.  Sertraline slows disease progression and increases neurogenesis in N171-82Q mouse model of Huntington's disease.

Authors:  Wenzhen Duan; Qi Peng; Naoki Masuda; Eric Ford; Erik Tryggestad; Bruce Ladenheim; Ming Zhao; Jean Lud Cadet; John Wong; Christopher A Ross
Journal:  Neurobiol Dis       Date:  2008-03-10       Impact factor: 5.996

Review 2.  Basal ganglia volumetric studies in affective disorder: what did we learn in the last 15 years?

Authors:  R M Bonelli; H-P Kapfhammer; S S Pillay; D A Yurgelun-Todd
Journal:  J Neural Transm (Vienna)       Date:  2005-10-27       Impact factor: 3.575

Review 3.  An overview of psychiatric symptoms in Huntington's disease.

Authors:  K E Anderson; K S Marder
Journal:  Curr Psychiatry Rep       Date:  2001-10       Impact factor: 5.285

4.  Gedunin Degrades Aggregates of Mutant Huntingtin Protein and Intranuclear Inclusions via the Proteasomal Pathway in Neurons and Fibroblasts from Patients with Huntington's Disease.

Authors:  Weiqi Yang; Jingmo Xie; Qiang Qiang; Li Li; Xiang Lin; Yiqing Ren; Wenlei Ren; Qiong Liu; Guomin Zhou; Wenshi Wei; Hexige Saiyin; Lixiang Ma
Journal:  Neurosci Bull       Date:  2019-08-20       Impact factor: 5.203

5.  Depressive-like behavior in mice recently recovered from motor disorders after 3-nitropropionic acid intoxication.

Authors:  Xiao-Min Li; Bing-Gen Zhu; Sha Ma; Wei Zhou; Zheng Wei; Yu-Xiang Zheng; Xu-Dong Zhao; Rong-Shen Zhu
Journal:  Neurosci Bull       Date:  2008-08       Impact factor: 5.203

6.  Brain volume abnormalities in major depressive disorder: a meta-analysis of magnetic resonance imaging studies.

Authors:  P Cédric M P Koolschijn; Neeltje E M van Haren; Gerty J L M Lensvelt-Mulders; Hilleke E Hulshoff Pol; René S Kahn
Journal:  Hum Brain Mapp       Date:  2009-11       Impact factor: 5.038

7.  The antidepressant sertraline improves the phenotype, promotes neurogenesis and increases BDNF levels in the R6/2 Huntington's disease mouse model.

Authors:  Qi Peng; Naoki Masuda; Mali Jiang; Qing Li; Ming Zhao; Christopher A Ross; Wenzhen Duan
Journal:  Exp Neurol       Date:  2007-11-09       Impact factor: 5.330

Review 8.  Bipolar and major depressive disorder: neuroimaging the developmental-degenerative divide.

Authors:  Jonathan Savitz; Wayne C Drevets
Journal:  Neurosci Biobehav Rev       Date:  2009-01-21       Impact factor: 8.989

9.  DISC1 and Huntington's disease--overlapping pathways of vulnerability to neurological disorder?

Authors:  Ruth Boxall; David J Porteous; Pippa A Thomson
Journal:  PLoS One       Date:  2011-01-26       Impact factor: 3.240

10.  Regional homogeneity abnormalities affected by depressive symptoms in migraine patients without aura: a resting state study.

Authors:  Dahua Yu; Kai Yuan; Ling Zhao; Fanrong Liang; Wei Qin
Journal:  PLoS One       Date:  2013-10-16       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.